Zydus Lifesciences gets EIR report with Nill observations from USFDA
The company has received the establishment inspection report for an inspection at the group’s manufacturing plant located SEZ - II, Ahmedabad
Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for an inspection at the group’s manufacturing plant located SEZ - II, Ahmedabad, from August 11, 2025 to August 14, 2025. The inspection was a Pre-Approval Inspection (PAI). The USFDA has concluded this inspection as closed. The inspection concluded with NIL observations. The EIR has classified the facility as No Action Indicated (NAI).
Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.
